Association of Inhaled Corticosteroids With All-Cause Mortality Risk in Patients With COPD

医学 慢性阻塞性肺病 内科学 随机对照试验 吸入性皮质类固醇 哮喘 科克伦图书馆
作者
Hong Chen,Zheng-Xu Deng,Jian Sun,Qiang Huang,Lan Huang,Yonghong He,Chunlan Ma,Ke Wang
出处
期刊:Chest [Elsevier]
卷期号:163 (1): 100-114 被引量:17
标识
DOI:10.1016/j.chest.2022.07.015
摘要

Background Inhaled corticosteroids (ICSs) have been used widely in the maintenance therapy of COPD. However, whether inhaled therapy containing ICSs can reduce the all-cause mortality risk and the possible benefited patient subgroups is unclear. Research Question Does inhaled therapy containing ICSs reduce the all-cause mortality risk in patients with COPD compared with other inhaled therapies not containing ICSs? Study Design and Methods We searched PubMed, Cochrane Library, Embase, and ClinicalTrials.gov for relevant randomized clinical trials (RCTs). Pooled results were calculated using Peto ORs with corresponding 95% CIs. Results Sixty RCTs enrolling 103,034 patients were analyzed. Inhaled therapy containing ICSs (Peto OR, 0.90; 95% CI, 0.84-0.97), especially triple therapy (Peto OR, 0.73; 95% CI, 0.60-0.90), was associated with a reduction in the all-cause mortality risk among patients with COPD when compared with inhaled therapy without ICSs. Subgroup analyses revealed that treatment duration of > 6 months (Peto OR, 0.90; 95% CI, 0.83-0.97), medium-dose ICSs (Peto OR, 0.71; 95% CI, 0.56-0.91), low-dose ICSs (Peto OR, 0.88; 95% CI, 0.79-0.97), and budesonide (Peto OR, 0.75; 95% CI, 0.59-0.94) were involved in this association. The predictors of this association included eosinophil counts of ≥ 200/μL or percentage of ≥ 2%, documented history of ≥ 2 moderate and severe exacerbations in the previous year, Global Initiative for Chronic Obstructive Lung Disease stages III or IV, age younger than 65 years, and BMI of ≥ 25 kg/m2, among which eosinophil counts of ≥ 200/μL (Peto OR, 0.58; 95% CI, 0.36-0.95) were the strongest predictor. Interpretation Inhaled therapy containing ICSs, especially triple therapy, of longer than 6 months was associated with a reduction in the all-cause mortality risk in patients with COPD. The predictors of this association included medication factors and patient characteristics, among which eosinophil counts of ≥ 200/μL were the strongest predictor. Trial Registry PROSPERO; No.: CRD42022304725; URL: https://www.crd.york.ac.uk/prospero/ Inhaled corticosteroids (ICSs) have been used widely in the maintenance therapy of COPD. However, whether inhaled therapy containing ICSs can reduce the all-cause mortality risk and the possible benefited patient subgroups is unclear. Does inhaled therapy containing ICSs reduce the all-cause mortality risk in patients with COPD compared with other inhaled therapies not containing ICSs? We searched PubMed, Cochrane Library, Embase, and ClinicalTrials.gov for relevant randomized clinical trials (RCTs). Pooled results were calculated using Peto ORs with corresponding 95% CIs. Sixty RCTs enrolling 103,034 patients were analyzed. Inhaled therapy containing ICSs (Peto OR, 0.90; 95% CI, 0.84-0.97), especially triple therapy (Peto OR, 0.73; 95% CI, 0.60-0.90), was associated with a reduction in the all-cause mortality risk among patients with COPD when compared with inhaled therapy without ICSs. Subgroup analyses revealed that treatment duration of > 6 months (Peto OR, 0.90; 95% CI, 0.83-0.97), medium-dose ICSs (Peto OR, 0.71; 95% CI, 0.56-0.91), low-dose ICSs (Peto OR, 0.88; 95% CI, 0.79-0.97), and budesonide (Peto OR, 0.75; 95% CI, 0.59-0.94) were involved in this association. The predictors of this association included eosinophil counts of ≥ 200/μL or percentage of ≥ 2%, documented history of ≥ 2 moderate and severe exacerbations in the previous year, Global Initiative for Chronic Obstructive Lung Disease stages III or IV, age younger than 65 years, and BMI of ≥ 25 kg/m2, among which eosinophil counts of ≥ 200/μL (Peto OR, 0.58; 95% CI, 0.36-0.95) were the strongest predictor. Inhaled therapy containing ICSs, especially triple therapy, of longer than 6 months was associated with a reduction in the all-cause mortality risk in patients with COPD. The predictors of this association included medication factors and patient characteristics, among which eosinophil counts of ≥ 200/μL were the strongest predictor. PROSPERO; No.: CRD42022304725; URL: https://www.crd.york.ac.uk/prospero/ Corrigendum to: CHEST 2023;163(1):100-114CHESTVol. 163Issue 5PreviewThe January 2023 original research article titled "Association of Inhaled Corticosteroids With All-Cause Mortality Risk in Patients With COPD: A Meta-analysis of 60 Randomized Controlled Trials" by Chen et al (CHEST. 2023;163[1]:100-114) contained the following errors: Full-Text PDF ResponseCHESTVol. 163Issue 5PreviewWe thank Dr Oba for his interest in our study about the association of inhaled corticosteroids (ICSs) with all-cause mortality risk in patients with COPD.1 The data of our meta-analysis were completely extracted from the 60 included randomized controlled trials, as detailed in the online supplement of the article. We agree with some of the comments from Dr Oba on data issues. These comments are of great value, help to improve our article, and have important guiding significance for our research. Full-Text PDF Data Collection Issues With Mortality Risk of Inhaled Corticosteroids in COPDCHESTVol. 163Issue 5PreviewThere appear to be major issues with the data collection and conduct of the meta-analysis by Chen et al1 in CHEST (January 2023). For instance, in Figure 3B, the authors included data of triple combinations for the inhaled corticosteroid/long-acting β2-agonist (ICS/LABA) arm in studies by Ferguson et al2(2018), Lipson et al3 (2018), and Rabe et al4 (2020). There are no qualifying data for this comparison in Chapman et al5 (2018) because there was no ICS/LABA arm. Ichinose et al6 (2019) and Kerwin et al7 (2019) are extension studies of Ferguson et al2 (2018) (KRONOS), which could introduce bias because of withdrawals due to death before the extension portion of the studies. Full-Text PDF ResponseCHESTVol. 162Issue 6PreviewIn response to Dr Samy Suissa's comments on the article "Association of Inhaled Corticosteroids With All-cause Death Risk in COPD Patients: A Meta-analysis of Sixty Randomized Controlled Trials,"1 our responses are as follows: Full-Text PDF Inhaled Corticosteroids and Mortality in COPD: Biases in Randomized TrialsCHESTVol. 162Issue 6PreviewThe meta-analysis of 60 randomized trials by Chen et al1 in CHEST reports that inhaled corticosteroids (ICS) to treat COPD reduce all-cause mortality by 10% (OR, 0.90; 95% CI, 0.84-0.97) and up to 40% in some subgroups.1 We note from Figure 2 of Chen et al that the pooled results are largely driven by three large trials, SUMMIT, IMPACT, and ETHOS, the latter two contributing 41% and 32% reductions in mortality with ICS use, respectively. However, the design of these triple-therapy trials included patients already treated with maintenance therapy that had to be abruptly discontinued before randomization, which could affect the results. Full-Text PDF Inhaled Corticosteroids and COPD: 25 Years Later and We Are Still Not ThereCHESTVol. 163Issue 1PreviewAlready in 2007, the Towards a Revolution in COPD Health (TORCH) trial1 provided the strong tendency toward significance (P = .052) that an inhaled corticosteroid/long-acting β2-adrenoceptor agonist (inhaled corticosteroids [ICS]/long-acting beta-agonists [LABA]) fixed-dose combination (FDC) may reduce the risk of death in patients with COPD vs placebo (hazard ratio [HR] 0.825, 95% CI, 0.681-1.002). Although the TORCH study did not meet the predetermined level of statistical significance for the primary outcome of death from any cause, this trial was recognized as an example of trials whose findings are worthy of more constructive interpretation than that of negative trials. Full-Text PDF
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
专注的飞瑶完成签到 ,获得积分10
刚刚
木雨亦潇潇完成签到,获得积分10
2秒前
Ava应助菜菜Cc采纳,获得10
2秒前
mzy发布了新的文献求助10
2秒前
3秒前
小龙完成签到,获得积分10
3秒前
bkagyin应助电催化托采纳,获得10
3秒前
Saven完成签到,获得积分10
3秒前
枫叶发布了新的文献求助10
4秒前
5秒前
小章完成签到,获得积分10
5秒前
hxx完成签到,获得积分10
6秒前
云_123发布了新的文献求助10
7秒前
siwei发布了新的文献求助10
9秒前
冷静的哈密瓜完成签到,获得积分10
10秒前
酷波er应助科研通管家采纳,获得10
15秒前
华仔应助科研通管家采纳,获得10
15秒前
科研通AI2S应助科研通管家采纳,获得10
15秒前
丘比特应助科研通管家采纳,获得10
15秒前
小二郎应助科研通管家采纳,获得10
15秒前
思源应助科研通管家采纳,获得10
15秒前
桐桐应助科研通管家采纳,获得10
15秒前
15秒前
我爱康康文献完成签到 ,获得积分10
15秒前
16秒前
电催化托完成签到,获得积分10
17秒前
17秒前
paopao发布了新的文献求助10
22秒前
pluto应助活力小熊猫采纳,获得10
22秒前
别让我误会完成签到 ,获得积分10
22秒前
纬宇发布了新的文献求助10
22秒前
电催化托发布了新的文献求助10
23秒前
聪明的灵寒完成签到 ,获得积分10
25秒前
阿呆在发呆完成签到,获得积分10
26秒前
菜菜Cc关注了科研通微信公众号
28秒前
28秒前
不配.应助paopao采纳,获得10
31秒前
yy发布了新的文献求助10
32秒前
36秒前
一二三完成签到 ,获得积分10
37秒前
高分求助中
Sustainability in Tides Chemistry 2800
The Young builders of New china : the visit of the delegation of the WFDY to the Chinese People's Republic 1000
Rechtsphilosophie 1000
Bayesian Models of Cognition:Reverse Engineering the Mind 888
Le dégorgement réflexe des Acridiens 800
Defense against predation 800
Very-high-order BVD Schemes Using β-variable THINC Method 568
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3134943
求助须知:如何正确求助?哪些是违规求助? 2785830
关于积分的说明 7774354
捐赠科研通 2441699
什么是DOI,文献DOI怎么找? 1298104
科研通“疑难数据库(出版商)”最低求助积分说明 625079
版权声明 600825